IQVIA Holdings Inc (IQV)vsNebius Group N.V. (NBIS)
IQV
IQVIA Holdings Inc
$173.55
-2.89%
HEALTHCARE · Cap: $29.83B
NBIS
Nebius Group N.V.
$221.15
+6.70%
COMMUNICATION SERVICES · Cap: $52.63B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 1795% more annual revenue ($16.63B vs $877.90M). NBIS leads profitability with a 93.1% profit margin vs 8.3%. NBIS appears more attractively valued with a PEG of 0.63. IQV earns a higher WallStSmart Score of 66/100 (B-).
IQV
Strong Buy66
out of 100
Grade: B-
NBIS
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.6%
Fair Value
$258.96
Current Price
$173.55
$85.41 discount
Margin of Safety
+33.0%
Fair Value
$309.18
Current Price
$221.15
$88.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Keeps 93 of every $100 in revenue as profit
Revenue surging 621.0% year-over-year
Large-cap with strong market position
Growing faster than its price suggests
Areas to Watch
Distress zone — elevated risk
Trading at 12.3x book value
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : NBIS
The strongest argument for NBIS centers on Profit Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 93.1% and operating margin at -32.1%. Revenue growth of 621.0% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : NBIS
The primary concerns for NBIS are Price/Book, EPS Growth, Debt/Equity. A P/E of 80.0x leaves little room for execution misses.
Key Dynamics to Monitor
IQV profiles as a value stock while NBIS is a growth play — different risk/reward profiles.
NBIS carries more volatility with a beta of 1.24 — expect wider price swings.
NBIS is growing revenue faster at 621.0% — sustainability is the question.
IQV generates stronger free cash flow (491M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (66/100 vs 53/100). NBIS offers better value entry with a 33.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Nebius Group N.V.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Nebius Group N.V. (Ticker: NBIS) is a forward-looking technology company specializing in advanced digital solutions designed to enhance client engagement and streamline operational efficiency across diverse sectors. By harnessing the power of cloud computing, artificial intelligence, and data analytics, Nebius equips businesses to effectively manage the complexities of the digital age. With a strong portfolio of intellectual property and meaningful strategic partnerships, the company is poised to capture significant growth opportunities in the dynamic technology landscape, positioning itself as an appealing investment choice for institutional investors seeking high-growth prospects in tech-driven markets.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?